Skip to main content
. Author manuscript; available in PMC: 2010 Aug 3.
Published in final edited form as: Lancet. 2009 Nov 21;374(9703):1754–1764. doi: 10.1016/S0140-6736(09)61492-6

Figure 1. LARGE study design.

Figure 1

Following screening and genotyping, genotype-eligible and matched subjects who received 8 weeks of ICS during the run-in were randomized to continue ICS with either LABA or placebo for 18 weeks, followed by an 8 week runout period on ICS alone, followed by the alternate treatment.